A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
Condition studied
Amyotrophic Lateral Sclerosis (ALS)
Investigational medicinal product(s)
Eligibility
Primary endpoint
Absolute change in ALSFRS-R total score from baseline to Week 24.
Endpoint detail
Mean rank for CAFS across all by treatment group at Week 24., Time to event requiring full-time or nearly full-time respiratory support., Mean change in %FVC from baseline to Week 24., Mean change in PIFR from baseline to Week 24.
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-520688-42-00 on CTIS ↗ ← All trials in the EU